J&J Revises Doxil Label To Include Cardiotoxicity Data For Liposomal Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
The risk of cardiotoxicity for liposomal doxorubicin is 11% based on a 250-patient breast cancer trial, updated labeling states. Labeling previously said that Doxil's myocardial toxicity would likely be similar to the risk of conventional formulations, which ranges from 6% to 20%.
You may also be interested in...
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).
Menactra Pricing Will Be In Line With Wyeth's Prevnar, Sanofi-Aventis Says
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar